Greek biotech research SME with experience in bio-based forestry products and durable materials for coastal infrastructure.
API Europe MEPE is a Greek biotechnology research and study services SME based in Athens, specialising in applied research across bio-based product development and advanced construction materials. Their company name literally translates as a single-member limited liability company for "research and study services in biotechnology," indicating a research services model rather than a product manufacturer. In BIOFOREVER they contributed to developing economically viable routes for converting forestry biomass into bio-based products under the Bio-based Industries joint undertaking. In ReSHEALience they shifted to investigating high-durability materials for coastal defence and green-energy infrastructure, suggesting a broad applied research portfolio rather than a narrow niche.
Participated in BIOFOREVER (2016–2019), an €18M+ BBI demonstration project developing economically viable European routes for converting forestry residues into bio-based chemicals and materials.
Company name and legal form indicate the core business is providing contracted research and analytical services in biotechnology, applied across both BIOFOREVER and ReSHEALience.
Contributed to ReSHEALience (2018–2022), an RIA project rethinking coastal defence and green-energy service infrastructure through enhanced-durability high-performance materials.
API Europe's two-project H2020 history shows a pivot from bio-based chemistry and forestry biorefinery (BIOFOREVER, 2016) toward construction materials science and infrastructure durability (ReSHEALience, 2018). This is a notable sector jump — from food-adjacent bio-based products to civil engineering materials — suggesting the company functions as a flexible research services provider rather than a deep domain specialist. No keyword metadata is available to confirm this interpretation, so the observed shift may reflect client-driven contract work rather than a deliberate strategic reorientation.
Their trajectory points toward applied materials research for climate-resilient infrastructure, but with only two completed projects and no post-2022 H2020 activity, it is unclear whether this direction will continue or whether they return to biotechnology and biorefinery as a base.
API Europe has always joined projects as a consortium participant, never serving as coordinator, which is consistent with a research services SME that provides specialist input rather than leading consortia. Both projects involved large multi-partner consortia — BIOFOREVER alone was a major BBI demonstration project — indicating comfort operating within complex, multi-national research frameworks. Their 35 unique partners across 13 countries relative to only 2 projects suggests they accessed diverse networks through these large consortia rather than through repeated bilateral relationships.
Despite only two projects, API Europe has built contact with 35 unique consortium partners across 13 countries, reflecting the large scale of the BIOFOREVER and ReSHEALience consortia. Their network skews toward European partners typical of BBI and Horizon RIA projects, with no evidence of a specific geographic concentration beyond Greece.
API Europe is one of very few Greek private SMEs active in both the Bio-based Industries Joint Undertaking space and construction materials RIA projects, which gives them an unusual cross-domain research services profile. For a consortium builder, they offer a Southern European SME slot combined with genuine biotechnology research competence — a combination that can strengthen geographic and organisational diversity requirements. However, their thin project record means a potential partner should seek direct conversation about current capabilities before drawing conclusions from their H2020 history alone.
